WASHINGTON, D.C. — In the high-stakes arena of federal budget negotiations, the battle against cancer is often fought not only in the laboratory but in the ledger. This week, METAvivor Research and Support, a leading non-profit dedicated to the specific needs of the metastatic breast cancer (MBC) community, formally signaled its entry into the fiscal year 2027 appropriations debate.
The organization has issued a comprehensive appeal to the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies. The core of their message is clear: without robust and expanded funding for the nation’s primary cancer registries—the Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries (NPCR) and the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) Program—the United States risks blinding its scientific community to the evolving reality of the disease.
Main Facts: The Infrastructure of Cancer Surveillance
At the heart of METAvivor’s advocacy is the assertion that data is the lifeblood of modern oncology. The NPCR and SEER programs represent the dual pillars of American cancer surveillance. Together, they collect, analyze, and disseminate data on cancer incidence, survival, and prevalence across the entire U.S. population.
The Role of NPCR and SEER
The CDC’s NPCR provides support for cancer registries in 45 states, the District of Columbia, Puerto Rico, and the U.S. Pacific Island Jurisdictions. It covers approximately 96% of the U.S. population. Conversely, the NCI’s SEER program focuses on high-quality, longitudinal data from specific geographic regions, covering about 48% of the population, and is often used for deeper epidemiological research and survival trend analysis.
The 2027 Funding Request
While the 2027 fiscal year may seem distant to the general public, the federal appropriations process requires multi-year foresight. METAvivor is urging Congress to not only maintain current funding levels but to increase them significantly. The organization argues that the current infrastructure is strained by the increasing complexity of cancer data, including the need to track recurrence and metastatic progression—areas that have historically been under-reported in traditional registry models.
Why METAvivor is Leading the Charge
METAvivor is unique in its focus on Stage IV, or metastatic, breast cancer—cancer that has spread beyond the breast to other organs. For years, the MBC community has highlighted a "data gap": most registries are designed to capture the initial diagnosis. If a patient is diagnosed with Stage II cancer that later recurs as Stage IV, that transition is not always captured with the same rigor as the initial diagnosis. METAvivor’s push for 2027 funding is specifically aimed at modernizing these registries to ensure every stage of the cancer journey is documented.
Chronology: The Evolution of Cancer Tracking in America
To understand the urgency of METAvivor’s current demand, one must look at the historical trajectory of how the United States has monitored the "War on Cancer."
1971–1973: The Foundation
The National Cancer Act of 1971, signed by President Richard Nixon, mandated the collection, analysis, and dissemination of data useful in the prevention, diagnosis, and treatment of cancer. This led to the establishment of the SEER program in 1973. Initially, SEER was a revolutionary step, providing the first real-time look at how cancer affected different demographics.
1992: Expanding the Scope
Recognizing that SEER did not cover the entire country, Congress established the NPCR through the Cancer Registries Amendment Act in 1992. This empowered the CDC to assist states in developing registries that met national standards for data quality and completeness.
2010s: The Rise of the "Counting MBC" Movement
In the last decade, advocacy groups like METAvivor began to point out a systemic flaw. While the number of new cancer cases was being tracked, the number of people living with metastatic disease was largely estimated rather than counted. In 2017, a landmark study estimated that over 150,000 women were living with MBC in the U.S., a number far higher than previously thought. This spurred a movement to "Count MBC," requiring more sophisticated data collection methods from SEER and NPCR.
2024–2025: The 2027 Planning Phase
As of late 2024, the federal government began the preliminary stages of the 2027 budget cycle. METAvivor’s recent letter to the Senate Appropriations Subcommittee serves as a preemptive strike to ensure that cancer surveillance is prioritized before the budget hardens into final drafts.
Supporting Data: The Quantitative Case for Funding
The push for increased funding is backed by sobering statistics and the economic realities of healthcare.
Prevalence and Incidence
According to the American Cancer Society, over 2 million new cancer cases are expected to be diagnosed in the U.S. in 2024. For breast cancer specifically, while the five-year survival rate for localized disease is 99%, that number drops to 31% for metastatic disease. METAvivor points out that without the granular data provided by registries, researchers cannot accurately determine which treatments are extending the lives of metastatic patients.
The Cost of Inaction
The economic burden of cancer in the U.S. is projected to rise to over $246 billion by 2030. Registries are considered high-yield investments. By identifying clusters of disease or disparities in treatment outcomes, registries allow for "precision public health"—directing resources where they are most needed, thereby reducing wasteful spending on ineffective interventions.
Addressing Disparities
Data from SEER and NPCR consistently show that Black women are 40% more likely to die from breast cancer than white women, despite having a lower or similar incidence rate. METAvivor argues that 2027 funding must include provisions for "enhanced data elements," such as social determinants of health (SDOH), to help researchers understand and close these mortality gaps.
Official Responses: Voices from the Hill and the Healthcare Sector
The response to METAvivor’s advocacy has been met with a mixture of support and the usual fiscal caution that characterizes the Senate Appropriations Subcommittee.
The Subcommittee’s Stance
While the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies has historically been bipartisan in its support for the NCI and CDC, the current economic climate has led to calls for "fiscal restraint." However, staffers close to the subcommittee indicate that cancer research remains one of the few areas where there is a general consensus for sustained investment.
CDC and NCI Perspectives
While federal agencies cannot lobby for their own funding, leadership at the CDC and NCI have frequently testified about the technological needs of their registries. The transition to "cloud-based" data reporting and the integration of electronic health records (EHRs) into registries are top priorities. These upgrades require significant capital investment, which aligns with METAvivor’s 2027 funding goals.
The Unified Advocacy Front
METAvivor is not alone. Their letter has been echoed by other major health organizations. A spokesperson for the American Association for Cancer Research (AACR) noted, "The infrastructure of our registries is the foundation upon which all clinical trials are built. You cannot design a trial for a population you haven’t accurately counted."
Implications: What is at Stake for 2027 and Beyond?
The outcome of this funding request will have ripples that last for decades. The implications of METAvivor’s success—or failure—to secure these funds are profound.
Precision Medicine and Targeted Therapies
We are entering an era of precision medicine where treatments are tailored to the genetic makeup of a specific tumor. Registries are beginning to collect genomic data, but this process is expensive. If the 2027 funding falls short, the U.S. may lose the ability to track how these high-cost, high-tech treatments are performing in the "real world" outside of controlled clinical trials.
The Risk of Data Blind Spots
If funding remains stagnant, registries may be forced to scale back the number of regions they cover or the depth of data they collect. This creates "blind spots," particularly in rural or underserved communities. For a metastatic patient in a rural area, the lack of data could mean their specific challenges—such as travel distance to specialized care—remain invisible to policymakers.
Future Pandemic Preparedness
The COVID-19 pandemic showed how quickly cancer screenings and treatments can be disrupted. Robust registries are essential for "disaster epidemiology," allowing health officials to see exactly how many diagnoses were missed during a crisis and where the resulting surge in late-stage diagnoses is occurring.
Conclusion: A Call to Action
METAvivor’s letter to the Senate is more than a request for money; it is a demand for visibility. For the hundreds of thousands of Americans living with metastatic cancer, being "counted" is the first step toward being cured. As the 2027 appropriations process moves forward, the advocacy of groups like METAvivor will be the deciding factor in whether the U.S. continues to lead the world in cancer surveillance or falls behind in the very data science it helped create.
"Consistent and strong support for these registries is essential in our fight against cancer," the organization stated. "We are weighing in now to ensure that when 2027 arrives, the data is ready, the researchers are empowered, and the patients are no longer invisible."
About the Author
